Clinical Trial Update: Placebo Controlled Study of 3 Doses of Rifaximin-EIR Tablet to Treat Moderate, Active Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 placebo-controlled trial evaluating three doses of rifaximin-EIR tablets for moderate to active Crohn's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Rifaximin-EIR Tablet (rifaximin)

Snippet

Sponsor: Alfasigma S.p.A. | Conditions: Crohn's Disease | Phase 2 | Status: COMPLETED